Neuland Laboratories Limited (NEULANDLAB)
Investor Presentation
AI summary
- Q2FY27 standalone revenue declined 11.4% YoY to ₹457.2 Cr; EBITDA down 33.4% YoY at ₹104.6 Cr with margin 22.9%
- Q2FY27 PAT fell 47.0% YoY to ₹51.1 Cr; EPS ₹39.9 vs ₹75.2 in Q2FY26
- H1FY27 revenue grew 35.6% YoY to ₹1107.2 Cr; EBITDA up 68.6% YoY at ₹335.6 Cr with margin 30.3%
- H1FY27 PAT rose 80.2% YoY to ₹198.5 Cr; working capital days improved to 104 from 155
- Capex of ₹261 Cr invested in new R&D and peptide block
- CMS business growth driven by commercial molecules and new project orders
- Specialty segment growth led by Ezetimibe and other key molecules
- CEO: Growth expectations intact for FY27 and next year despite Q2 dip
- Net debt improved to negative ₹208 Cr at Q2FY27 end
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NEULANDLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NEULANDLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Neuland Laboratories Limited
Important.
The summary above is generated automatically from Neuland Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.